View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
February 14, 2020

Codagenix partners Serum Institute of India on Covid-19 vaccine

Biotechnology firm Codagenix has partnered with vaccine manufacturer Serum Institute of India to work together for the development of a vaccine for the new coronavirus.


Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

Follow the latest updates of the outbreak on our timeline.

Biotechnology firm Codagenix has partnered with vaccine manufacturer Serum Institute of India to work together for the development of a vaccine for the new coronavirus.

The partners intend to develop a live-attenuated vaccine, which can induce an immune response to different antigens of the virus and enables scale for mass production, among other benefits.

Viral deoptimisation quickly synthesises live-attenuated vaccines. The company only requires information about the viral genome’s digital sequence to generate vaccine candidates.

For the new coronavirus, the company used its deoptimisation technology and designed several nCoV vaccine candidate genomes. The next step is to grow and conduct in-vivo tests of vaccine viruses before proceeding to clinical trials.

Serum Institute of India will contribute to the partnership by scaling the vaccine manufacturing.

Codagenix CEO J Robert Coleman said: “With the Serum Institute’s financial and technical support, we will be able to push a coronavirus vaccine into the clinic on an extremely rapid timeline.

“Live-attenuated vaccines like the ones developed by Codagenix are ideally suited to outbreak scenarios as they scale rapidly and generally require only modest amounts of active ingredient for each immunisation, as compared to inactivated and subunit vaccines.”

The partners have adopted an accelerated development pathway to make the vaccine available rapidly.

Serum Institute CEO Dr Adar Poonwalla said: “We are very excited for this new partnership with Codagenix and we hope that we can establish a platform dealing with new infectious diseases and outbreaks beginning with the coronavirus epidemic.”

Codagenix is among the many companies and research organisations that have initiated efforts to develop a vaccine and effective treatments for the new coronavirus that emerged in China.

Related Companies

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology